Latest Insider Transactions at Kymera Therapeutics, Inc. (KYMR)
This section provides a real-time view of insider transactions for Kymera Therapeutics, Inc. (KYMR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kymera Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kymera Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,939
-1.29%
|
$347,865
$35.22 P/Share
|
|
Apr 08
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,939
+2.51%
|
$19,878
$2.08 P/Share
|
|
Mar 15
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,195
-100.0%
|
$491,700
$60.17 P/Share
|
|
Mar 15
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,195
+50.0%
|
$16,390
$2.08 P/Share
|
|
Mar 15
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,305
-19.5%
|
$618,300
$60.17 P/Share
|
|
Mar 15
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,800
+12.86%
|
$7,800
$1.31 P/Share
|
|
Mar 12
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
229,350
-100.0%
|
$12,843,600
$56.5 P/Share
|
|
Mar 12
2021
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
229,350
-100.0%
|
$12,843,600
$56.5 P/Share
|
|
Mar 11
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,805
-100.0%
|
$108,300
$60.07 P/Share
|
|
Mar 11
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,805
+50.0%
|
$3,610
$2.08 P/Share
|
|
Mar 11
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,695
-9.44%
|
$281,700
$60.05 P/Share
|
|
Mar 11
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+4.24%
|
$2,200
$1.31 P/Share
|
|
Mar 08
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-92.32%
|
$510,000
$51.3 P/Share
|
|
Mar 08
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.08 P/Share
|
|
Mar 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-75.34%
|
$880,000
$44.98 P/Share
|
|
Mar 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$40,000
$2.08 P/Share
|
|
Feb 24
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,675
-15.43%
|
$433,750
$50.91 P/Share
|
|
Feb 23
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,285
-25.54%
|
$944,965
$49.65 P/Share
|
|
Feb 22
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,104
-10.76%
|
$473,408
$52.63 P/Share
|
|
Feb 19
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,887
-9.51%
|
$488,785
$55.09 P/Share
|
|
Feb 18
2021
|
Atlas Venture Fund X, L.P. |
SELL
Other acquisition or disposition
|
Direct |
1,063,351
-13.38%
|
-
|
|
Feb 18
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,499
-6.5%
|
$357,445
$55.94 P/Share
|
|
Feb 17
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,550
-7.02%
|
$437,900
$58.39 P/Share
|
|
Aug 25
2020
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,630,660
+50.0%
|
-
|
|
Aug 21
2020
|
Bvf Partners L P Director |
BUY
Grant, award, or other acquisition
|
Direct |
978,693
+27.55%
|
$19,573,860
$20.0 P/Share
|
|
Aug 21
2020
|
Bvf Partners L P Director |
BUY
Conversion of derivative security
|
Direct |
1,578,804
+50.0%
|
-
|